JNJ Options Signal Battle for $235–$250 Range: Here’s How to Play the RSI Bounce and Bullish Catalysts

• JNJ opens bearish but still clings to key long-term support at the 200D MA.
• Options data shows heavy call interest at $250 and a massive $200 put wall building ahead.
• FDA approval of ICOTYDE™ and institutional buying hint at a bullish rebound.

Here’s the thing: JNJ is stuck in a tug-of-war. The stock is down almost 0.2% intraday but still holds above the $235 level. The long-term trend — supported by a 200D MA at $193 and a 30D MA at $242 — is bullish. That’s the big picture. But today’s short-term bearishness, paired with a RSI of 37.7 and MACD crossing below the signal line, means we’re in a setup that’s ripe for a bounce — if we know where to look.

The Options Battle for $235–$250 Shows a Key Sentiment Divide

Looking at options, the market isn’t neutral. The top call strike is at $250, with 4,899 contracts in open interest for the this Friday’s expiry. That’s a strong bet on a near-term rally. Then, at $240 and $247.5, we see more call OI — all expiring this week. That means a lot of traders are pricing in a sharp rebound before the weekend.

On the put side, though, the action is more ominous. The $200 put strike has a massive 11,150 contracts in open interest — a deep floor if the stock stumbles. This is a bearish wall, and if JNJ breaks below $238 (its lower Bollinger Band), that $200 level becomes a psychological anchor that could take the stock down quickly.

What’s especially interesting is the lack of major block trades — no whales moving in. That means retail and institutional options players are calling the shots right now. The put/call ratio is nearly even (0.986), but the skew is clearly in the direction of $235 to $250. That’s where the battle is, and it’s where the opportunity is.

FDA Approval and Institutional Buying Line Up to Support the Bull Case

Just a few days ago, JNJ scored a major win with FDA approval of ICOTYDE™, a first-in-class oral psoriasis treatment. In clinical trials, it showed impressive results — 70% of patients achieved clear or almost clear skin, and the safety profile was solid through Year 1. That’s a product with strong commercial potential and could drive earnings visibility for the rest of the year.

On top of that, institutions are buying in. HSBC upgraded JNJ to “buy” with a $280 price target — that’s nearly 18% upside from today’s price. Livforsakringsbolaget Skandia increased its stake by 44% to 195K shares. These are signals that the fundamentals are improving, even if the stock is getting hammered a bit today on short-term technicals.

How to Position: Stock and Options Setups for Today

If you’re a stock trader: consider entry near $237.50–$238 with a stop just below $235. The 200D MA is a long-term floor, and if the stock holds there, the bounce to $240 or $242 could be in play. A breakout above $243.30 (the 30D support zone) would confirm a shift in short-term sentiment.

For options players, look at:

• JNJ20260320C250 (250 Call, Expiring Friday): This is the most heavily bid strike with 4,899 OI. If JNJ bounces off $238 and pops above $242, this could move fast.
• JNJ20260327P235 (235 Put, Expiring Next Friday): A safer play if you want to hedge or go short-term bearish. The $235 level is a key support zone; if the stock breaks there, the put could catch a sharp move down.
• JNJ20260320P200 (200 Put, Expiring Friday): A deep bearish play for the most aggressive traders. This is where the puts are concentrated, and if JNJ cracks $235, this could be a big move.

Volatility on the Horizon: Where to Watch as the Week Unfolds

JNJ is at a crossroads. The options market is betting on a $235–$250 range, and the fundamentals are starting to turn bullish. But the near-term RSI is oversold, and the MACD is bearish. That means the next few hours or days could bring a sharp reversal — or a breakdown. Keep your eyes on the $238 level. If JNJ holds there and moves above $240, look for more call action. If it breaks below $235, the puts could get aggressive. Either way, the next 48 hours are going to tell a story. You might as well read it from the front row.

Look, I don’t know if JNJ is going to blow through $250 or if it’ll fall to $200. But I do know that the options market is already betting on one of those paths — and it’s time to pick a side.